| Characteristics . | HIV KS (n = 11) . | HIV Controls (n = 11) . | P Value HIV+ . | cKS− (n = 11) . | CControls (n = 11) . | P Value HIV– . | P Value HIV KS vs cKS . |
|---|---|---|---|---|---|---|---|
| Age, y | … | … | … | … | |||
| Mean (SD) | 53 (8.4) | 53 (8.2) | 1.00 | 75 (8.5) | 75 (6.4) | 1.00 | <.001 |
| Range | 38–65 | 35–60 | 59–89 | 69–89 | |||
| Sex, no. (%) | … | … | … | … | … | .15 | |
| Male | 11 (100%) | 11 (100%) | 1.00 | 9 (82%) | 9 (82%) | 1.00 | |
| Female | 0 | 0 | 1.00 | 2 (18%) | 2 (18%) | 1.00 | |
| MSM, no. (%) | 11 (100%) | 11 (100%) | 1.00 | 3 (27%) | 3 (27%) | 1.00 | <.001 |
| Diabetes, no. (%) | 1 (9%) | 3 (27%) | .29 | 1 (9%) | 1 (9%) | 1.00 | 1.00 |
| Hypertension, no. (%) | 1 (9%) | 2 (18%) | .56 | 2 (18%) | 3 (27%) | .63 | .56 |
| Statin use, no. (%) | 1 (9%) | 2 (18%) | .56 | 3 (27%) | 2 (18%) | .63 | .29 |
| Current/former smoker, no. (%) | 4 (36%) | 6 (55%) | .42 | 3 (27%) | 3 (9%) | 1.00 | .67 |
| CMV seropositivity, no. (%) | 11 (100%) | 11 (100%) | 1.00 | 9 (82%) | 9 (82%) | 1.00 | .15 |
| CD4 T cells/µL median (range) | 621 (114–1099) | 585 (398–967) | .79 | 416 (46–730) | 897 (518–1271) | <.001 | .11 |
| CD8 T cells/µL median (range) | 507 (379–1919) | 473 (224–1116) | .17 | 339 (200–582) | 415 (186–948) | .22 | .04 |
| CD4:CD8 ratio median (range) | 0.84 (0.34–1.25) | 1.16 (0.48–2.30) | .05 | 1.72 (0.75–1.90) | 1.9 (1.06–6.08) | .09 | .008 |
| HIV viral load, log10 copies/mL | <1.7 | <1.7 | 1.00 | N/A | N/A | N/A | N/A |
| HIV duration (y) Median (range) | 12.9 (2.8–28.7) | 16.7 (2.2–34.0) | .27 | N/A | N/A | N/A | N/A |
| ART use, no. (%) | 11 (100%) | 11 (100%) | 1.00 | N/A | N/A | N/A | N/A |
| PI use, no. (%) | 0 | 0 | 1.00 | N/A | N/A | N/A | N/A |
| ART duration, y | 12a | 16 | .26 | N/A | N/A | N/A | N/A |
| Anti-HHV8 IgG positive, no. (%) | 11 (100) | 10 (91) | .31 | 11 (100) | 1 (9) | <.01 | 1.0 |
| Characteristics . | HIV KS (n = 11) . | HIV Controls (n = 11) . | P Value HIV+ . | cKS− (n = 11) . | CControls (n = 11) . | P Value HIV– . | P Value HIV KS vs cKS . |
|---|---|---|---|---|---|---|---|
| Age, y | … | … | … | … | |||
| Mean (SD) | 53 (8.4) | 53 (8.2) | 1.00 | 75 (8.5) | 75 (6.4) | 1.00 | <.001 |
| Range | 38–65 | 35–60 | 59–89 | 69–89 | |||
| Sex, no. (%) | … | … | … | … | … | .15 | |
| Male | 11 (100%) | 11 (100%) | 1.00 | 9 (82%) | 9 (82%) | 1.00 | |
| Female | 0 | 0 | 1.00 | 2 (18%) | 2 (18%) | 1.00 | |
| MSM, no. (%) | 11 (100%) | 11 (100%) | 1.00 | 3 (27%) | 3 (27%) | 1.00 | <.001 |
| Diabetes, no. (%) | 1 (9%) | 3 (27%) | .29 | 1 (9%) | 1 (9%) | 1.00 | 1.00 |
| Hypertension, no. (%) | 1 (9%) | 2 (18%) | .56 | 2 (18%) | 3 (27%) | .63 | .56 |
| Statin use, no. (%) | 1 (9%) | 2 (18%) | .56 | 3 (27%) | 2 (18%) | .63 | .29 |
| Current/former smoker, no. (%) | 4 (36%) | 6 (55%) | .42 | 3 (27%) | 3 (9%) | 1.00 | .67 |
| CMV seropositivity, no. (%) | 11 (100%) | 11 (100%) | 1.00 | 9 (82%) | 9 (82%) | 1.00 | .15 |
| CD4 T cells/µL median (range) | 621 (114–1099) | 585 (398–967) | .79 | 416 (46–730) | 897 (518–1271) | <.001 | .11 |
| CD8 T cells/µL median (range) | 507 (379–1919) | 473 (224–1116) | .17 | 339 (200–582) | 415 (186–948) | .22 | .04 |
| CD4:CD8 ratio median (range) | 0.84 (0.34–1.25) | 1.16 (0.48–2.30) | .05 | 1.72 (0.75–1.90) | 1.9 (1.06–6.08) | .09 | .008 |
| HIV viral load, log10 copies/mL | <1.7 | <1.7 | 1.00 | N/A | N/A | N/A | N/A |
| HIV duration (y) Median (range) | 12.9 (2.8–28.7) | 16.7 (2.2–34.0) | .27 | N/A | N/A | N/A | N/A |
| ART use, no. (%) | 11 (100%) | 11 (100%) | 1.00 | N/A | N/A | N/A | N/A |
| PI use, no. (%) | 0 | 0 | 1.00 | N/A | N/A | N/A | N/A |
| ART duration, y | 12a | 16 | .26 | N/A | N/A | N/A | N/A |
| Anti-HHV8 IgG positive, no. (%) | 11 (100) | 10 (91) | .31 | 11 (100) | 1 (9) | <.01 | 1.0 |
Abbreviations: ART, antiretroviral therapy; CMV, cytomegalovirus; KS, Kaposi sarcoma; MSM, men who have sex with men; N/A, not applicable or not available; PI, protease inhibitor.
aData not available for 1 participant.
| Characteristics . | HIV KS (n = 11) . | HIV Controls (n = 11) . | P Value HIV+ . | cKS− (n = 11) . | CControls (n = 11) . | P Value HIV– . | P Value HIV KS vs cKS . |
|---|---|---|---|---|---|---|---|
| Age, y | … | … | … | … | |||
| Mean (SD) | 53 (8.4) | 53 (8.2) | 1.00 | 75 (8.5) | 75 (6.4) | 1.00 | <.001 |
| Range | 38–65 | 35–60 | 59–89 | 69–89 | |||
| Sex, no. (%) | … | … | … | … | … | .15 | |
| Male | 11 (100%) | 11 (100%) | 1.00 | 9 (82%) | 9 (82%) | 1.00 | |
| Female | 0 | 0 | 1.00 | 2 (18%) | 2 (18%) | 1.00 | |
| MSM, no. (%) | 11 (100%) | 11 (100%) | 1.00 | 3 (27%) | 3 (27%) | 1.00 | <.001 |
| Diabetes, no. (%) | 1 (9%) | 3 (27%) | .29 | 1 (9%) | 1 (9%) | 1.00 | 1.00 |
| Hypertension, no. (%) | 1 (9%) | 2 (18%) | .56 | 2 (18%) | 3 (27%) | .63 | .56 |
| Statin use, no. (%) | 1 (9%) | 2 (18%) | .56 | 3 (27%) | 2 (18%) | .63 | .29 |
| Current/former smoker, no. (%) | 4 (36%) | 6 (55%) | .42 | 3 (27%) | 3 (9%) | 1.00 | .67 |
| CMV seropositivity, no. (%) | 11 (100%) | 11 (100%) | 1.00 | 9 (82%) | 9 (82%) | 1.00 | .15 |
| CD4 T cells/µL median (range) | 621 (114–1099) | 585 (398–967) | .79 | 416 (46–730) | 897 (518–1271) | <.001 | .11 |
| CD8 T cells/µL median (range) | 507 (379–1919) | 473 (224–1116) | .17 | 339 (200–582) | 415 (186–948) | .22 | .04 |
| CD4:CD8 ratio median (range) | 0.84 (0.34–1.25) | 1.16 (0.48–2.30) | .05 | 1.72 (0.75–1.90) | 1.9 (1.06–6.08) | .09 | .008 |
| HIV viral load, log10 copies/mL | <1.7 | <1.7 | 1.00 | N/A | N/A | N/A | N/A |
| HIV duration (y) Median (range) | 12.9 (2.8–28.7) | 16.7 (2.2–34.0) | .27 | N/A | N/A | N/A | N/A |
| ART use, no. (%) | 11 (100%) | 11 (100%) | 1.00 | N/A | N/A | N/A | N/A |
| PI use, no. (%) | 0 | 0 | 1.00 | N/A | N/A | N/A | N/A |
| ART duration, y | 12a | 16 | .26 | N/A | N/A | N/A | N/A |
| Anti-HHV8 IgG positive, no. (%) | 11 (100) | 10 (91) | .31 | 11 (100) | 1 (9) | <.01 | 1.0 |
| Characteristics . | HIV KS (n = 11) . | HIV Controls (n = 11) . | P Value HIV+ . | cKS− (n = 11) . | CControls (n = 11) . | P Value HIV– . | P Value HIV KS vs cKS . |
|---|---|---|---|---|---|---|---|
| Age, y | … | … | … | … | |||
| Mean (SD) | 53 (8.4) | 53 (8.2) | 1.00 | 75 (8.5) | 75 (6.4) | 1.00 | <.001 |
| Range | 38–65 | 35–60 | 59–89 | 69–89 | |||
| Sex, no. (%) | … | … | … | … | … | .15 | |
| Male | 11 (100%) | 11 (100%) | 1.00 | 9 (82%) | 9 (82%) | 1.00 | |
| Female | 0 | 0 | 1.00 | 2 (18%) | 2 (18%) | 1.00 | |
| MSM, no. (%) | 11 (100%) | 11 (100%) | 1.00 | 3 (27%) | 3 (27%) | 1.00 | <.001 |
| Diabetes, no. (%) | 1 (9%) | 3 (27%) | .29 | 1 (9%) | 1 (9%) | 1.00 | 1.00 |
| Hypertension, no. (%) | 1 (9%) | 2 (18%) | .56 | 2 (18%) | 3 (27%) | .63 | .56 |
| Statin use, no. (%) | 1 (9%) | 2 (18%) | .56 | 3 (27%) | 2 (18%) | .63 | .29 |
| Current/former smoker, no. (%) | 4 (36%) | 6 (55%) | .42 | 3 (27%) | 3 (9%) | 1.00 | .67 |
| CMV seropositivity, no. (%) | 11 (100%) | 11 (100%) | 1.00 | 9 (82%) | 9 (82%) | 1.00 | .15 |
| CD4 T cells/µL median (range) | 621 (114–1099) | 585 (398–967) | .79 | 416 (46–730) | 897 (518–1271) | <.001 | .11 |
| CD8 T cells/µL median (range) | 507 (379–1919) | 473 (224–1116) | .17 | 339 (200–582) | 415 (186–948) | .22 | .04 |
| CD4:CD8 ratio median (range) | 0.84 (0.34–1.25) | 1.16 (0.48–2.30) | .05 | 1.72 (0.75–1.90) | 1.9 (1.06–6.08) | .09 | .008 |
| HIV viral load, log10 copies/mL | <1.7 | <1.7 | 1.00 | N/A | N/A | N/A | N/A |
| HIV duration (y) Median (range) | 12.9 (2.8–28.7) | 16.7 (2.2–34.0) | .27 | N/A | N/A | N/A | N/A |
| ART use, no. (%) | 11 (100%) | 11 (100%) | 1.00 | N/A | N/A | N/A | N/A |
| PI use, no. (%) | 0 | 0 | 1.00 | N/A | N/A | N/A | N/A |
| ART duration, y | 12a | 16 | .26 | N/A | N/A | N/A | N/A |
| Anti-HHV8 IgG positive, no. (%) | 11 (100) | 10 (91) | .31 | 11 (100) | 1 (9) | <.01 | 1.0 |
Abbreviations: ART, antiretroviral therapy; CMV, cytomegalovirus; KS, Kaposi sarcoma; MSM, men who have sex with men; N/A, not applicable or not available; PI, protease inhibitor.
aData not available for 1 participant.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
